The topical delivery of the non-steroidal anti-inflammatory drug, piroxicam, for the treatment of local inflammatroy conditions, represents a useful alternative to oral administration and the associated side-effects due to the systemic exposure of the patient to relatively high plasma concentration. However, the passive diffusion of piroxicam across the skin is relatively low ~(1) and its efficient dermal delivery requires, therefore, an enhancement strategy.
展开▼
